Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study-Reference-Cited by-同舟云学术

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Published:2015-06-20 Issue:1 Volume:5 Page:
ISSN:2191-219X
Container-title:EJNMMI Research
language:en
Short-container-title:EJNMMI Res

Author:

Ahmadzadehfar Hojjat,Rahbar Kambiz,Kürpig Stefan,Bögemann Martin,Claesener Michael,Eppard Elisabeth,Gärtner Florian,Rogenhofer Sebastian,Schäfers Michael,Essler Markus

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1186/s13550-015-0114-2.pdf

Reference24 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210 .

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi: 10.3322/caac.20073 .

3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506 .

4. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. doi: 10.1016/S1470-2045(14)71205-7 .

5. Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, et al. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):167–74. doi: 10.1038/sj.pcan.4500933 .

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Theranostics With 177Lu-PSMA;Seminars in Nuclear Medicine;2024-07

2. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going;Cancer Treatment Reviews;2024-06

3. Determination of Optimum Imaging Numbers for <sup>177</sup>Lu-PSMA Radionuclide Treatment Dosimetric Calculation;Istanbul Medical Journal;2024-05-24

4. Dosimetry for Radiopharmaceutical Therapy;2024-04

5. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice;Current Oncology;2024-03-07